Evidence map›Paper›PMID 42498876›Full record

ArticleInternational journal of hematology2026

Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients.

Emi Yokoyama, Taisuke Harada, Tomoyuki Endo, Hideki Goto, Junichi Sugita, Masayuki Aiba, Mutsumi Takahata, Takuto Miyagishima, Hajime Senjo, Satoshi Iyama and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Emi YokoyamaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan. chatte_brillante@yahoo.co.jp.ORCID http://orcid.org/0000-0002-1207-2138
Taisuke HaradaDepartment of Diagnostic Imaging, Hokkaido University Hospital, Sapporo, Japan.
Tomoyuki EndoDepartment of Infection Control and Prevention, Hokkaido University Hospital, Sapporo, Japan.
Hideki GotoDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Junichi SugitaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Masayuki AibaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Mutsumi TakahataDepartment of Hematology, Sapporo Kosei General Hospital, Sapporo, Japan.
Takuto MiyagishimaDepartment of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.
Hajime SenjoDepartment of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.
Satoshi IyamaDepartment of Hematology, Sapporo Medical University Hospital, Sapporo, Japan.
Shuichiro TakahashiDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Masayo YamamotoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Motohiro ShindoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Kazuya SatoDepartment of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan.
Junichi HashiguchiDepartment of Hematology, Kitami Red Cross Hospital, Kitami, Japan.
Tatsuo OyakeDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system (CNS) observed in immunocompromised individuals. We retrospectively evaluated the clinical courses of PML in patients with hematological malignancies at North Japan Hematology Study Group institutions, using patients with human immunodeficiency virus (HIV) infection as a reference. Eight PML patients had hematological malignancies and 9 had HIV infection. CD4 + T cell counts were markedly low in patients with hematological malignancies (median 168/μl, range 48.4-330/μl) and did not differ significantly from those in patients with HIV infection (median 28/μl, range 8-225.4/μl). IgG levels were significantly lower in patients with hematological malignancies (median 643.5 mg/dL, range 205-2478 mg/dL) than in patients with with HIV infection (median 1691.5 mg/dL, range 1304-3014 mg/dL) (p < 0.01). Almost all patients with hematological malignancies died after progression of PML (median time from onset to death, 136 days). In contrast, seven patients with HIV infection were alive at the end of follow-up. The incidence of PML in patients with hematological malignancies may increase with the introduction of new antibody drugs and cellular therapies in future. Considering the poor prognosis, greater caution is warranted regarding this serious complication.

Indexed as

Hematological malignanciesHuman immunodeficiency virus infectionProgressive multifocal leukoencephalopathy

Identifiers

PMID42498876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.